Soligenix, Inc. (SNGX) – StreetInsider.com Reports
-
Soligenix, Inc. (SNGX) Prices $4.75 Million Public Offering
-
Soligenix, Inc. (SNGX) Announces FDA Grants Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
-
Soligenix (SNGX) Granted FDA Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
-
Soligenix (SNGX) Enters Agreement with EMA on Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte
-
Soligenix, Inc. (SNGX) Files for Share and Warrant Offering
-
Soligenix, Inc. (SNGX) Files for 13.51M Share and Warrant Offering
-
Soligenix, Inc. (SNGX) Forms Behçet's Disease Medical Advisory Board
-
Soligenix, Inc. (SNGX)Announces FDA Grants "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
Soligenix (SNGX) Reports Top-line Results of the Phase 2a Study of SGX302
-
Soligenix (SNGX) Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
Soligenix (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
-
Soligenix, Inc. (SNGX) Tops Q3 EPS by 13c
-
Soligenix, Inc. (SNGX) Achieves Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High Temperatures
-
Soligenix, Inc. (SNGX) Files $50M Mixed Shelf
-
Soligenix, Inc. (SNGX) Tops Q2 EPS by 16c
-
Soligenix (SNGX) Announces Expansion of SGX302 Phase 2a Study
-
Soligenix, Inc. (SNGX) Announces Scheduling of Type A Meeting with FDA to Review Study Design for a Second Phase 3 Study of HyBryte
-
Soligenix, Inc. (SNGX) Prices 6.54M Share Offering at $1.30/sh
-
Soligenix, Inc. (SNGX) Announces $12M Share and Warrant Offering
-
Soligenix, Inc. (SNGX) Climbs 220% Following Positive Clinical Results from Compatibility Study of HyBryte
-
Soligenix, Inc. (SNGX) Reports Positive Clinical Results from Compatibility Study of HyBryte
-
Soligenix (SNGX) Enters Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease
-
Soligenix, Inc. (SNGX) Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) Files for $12M Share and Warrant Offering
-
Soligenix (SNGX) Provides Regulatory Update on HyBryte
-
Soligenix (SNGX) Receives USAN Approval for "Hypericin Sodium" as Nonproprietary Name for Novel Active Ingredient in HyBryte™ and SGX302
-
Soligenix (SNGX) Announces Scheduling of Type A Meeting with the U.S. FDA for HyBryte New Drug Application
-
Soligenix (SNGX) Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) Receives Refusal to File Letter from U.S. FDA for HyBryte NDA in the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) Halted, News Pending
-
Soligenix, Inc. (SNGX) Announces 1-for-15 Reverse Stock Split
-
Soligenix, Inc. (SNGX) Submits NDA for HyBryte
-
Soligenix, Inc. (SNGX) to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
-
Soligenix, Inc. (SNGX) Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
-
Soligenix, Inc. (SNGX) Announces $2.6M FDA Grant for Expanded Study of Hybryte
-
Soligenix, Inc. (SNGX) Awarded $2.6 Million FDA Orphan Products Development Grant for Expanded Study of HyBryte
-
Soligenix, Inc. (SNGX) Announces FDA Agreement on Initial Pediatric Study Plan for HyBryte
-
Soligenix, Inc. (SNGX) and SERB Pharmaceuticals Partner for Supply of Ricin Antigen
-
Soligenix (SNGX) Announces Publication of HyBryte Phase 3 FLASH Study for Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix, Inc. (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
-
Soligenix, Inc. (SNGX) Reports Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix, Inc. (SNGX) eceived a Notice of Allowance for its US patent application 16/879,668 - Patent Grants
-
Soligenix (SNGX) Receives $1.4M in Non-Dilutive Government Funding
-
Soligenix's (SNGX) CiVax Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
-
Soligenix, Inc. (SNGX) Issues Corporate Update on NDA Plans for HyBryte
-
Soligenix, Inc. (SNGX) Announces Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
-
Soligenix, Inc. (SNGX) Reports Successful Protection from Sudan Ebolavirus with a Bivalent Thermostabilized Filovirus Vaccine
-
Soligenix, Inc. (SNGX) Granted UK Pediatric Investigational Plan Waiver for HyBryte in CTCL
-
Soligenix, Inc. (SNGX) Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax Vaccine
-
Soligenix (SNGX) Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
Back to SNGX Stock Lookup
